A new ultra-low-dose combination oral contraceptive.

Abstract

Data were compiled from 17 U.S. sites during a study of levonorgestrel, 0.15 mg, and ethinyl estradiol, 0.03 mg. A total of 1,130 women participated in 11,604 cycles of treatment. Efficacy, cycle characteristics, bleeding irregularities and side effects were studied. Weight and blood pressure means were analyzed with the paired t-test. Subject acceptance of this new combination oral contraceptive was high.

• Authors: T B Woutersz
• Journal: The Journal of reproductive medicine (J Reprod Med) Vol. 28 Issue 1 Suppl Pg. 81-4 (Jan 1983) ISSN: 0024-7758 [Print] United States
• PMID: 6403705 (Publication Type: Journal Article)

Chemical References

• Contraceptives, Oral
• Contraceptives, Oral, Combined
• Contraceptives, Oral, Synthetic
• Norgestrel
• Ethinyl Estradiol
• Levonorgestrel

Topics

• Adolescent
• Adult
• Amenorrhea (chemically induced)
• Blood Pressure (drug effects)
• Body Weight (drug effects)
• Contraceptives, Oral (administration & dosage)
• Contraceptives, Oral, Combined (administration & dosage, adverse effects)
• Contraceptives, Oral, Synthetic (administration & dosage, adverse effects)
• Ethinyl Estradiol (administration & dosage, adverse effects)
• Female
• Humans
• Levonorgestrel
• Menstruation (drug effects)
• Norgestrel (administration & dosage, adverse effects)
• Stereoisomerism